Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Bladder cancer
Stage/Subtype:  stage IV bladder cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 54 for your search:
Start Over
A Study of Atezolizumab Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29294, NCI-2015-00200, 2014-003231-19, NCT02302807
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15679, NCI-2015-02085, 2014-003655-66, I4T-MC-JVDC, NCT02426125
Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Bladder Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D419BC00001, NCI-2015-02054, NCT02516241
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients with Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8027, NCI-2013-01614, NCT01938573
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-06, NCI-2015-02086, NCT02543645
Gemcitabine Hydrochloride and Cisplatin in Treating Patients with High-Grade Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-208, NCI-2010-02376, NCT01261728
Gemcitabine Hydrochloride, Cisplatin, and Ipilimumab as First-Line Therapy in Treating Patients With Metastatic Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU10-148, NCI-2013-00250, 1110007307, NCT01524991
Cabozantinib-S-Malate in Treating Patients with Metastatic Bladder Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-C-0205, NCI-2013-01555, 120205, 12-C-0205J, P11900, 9236, NCT01688999
3D Conformal Radiation Therapy after Surgery in Treating Patients with High-Risk Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RAD2271-12, NCI-2013-01381, IRB00059097, NCT01954173
Gene Expression Profiling in Predicting Chemotherapy Response in Patients with Localized, Muscle-Invasive Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1314, NCI-2014-00850, NCT02177695
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients with Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PHII-130, NCI-2014-01294, P9653_A02PAMDREVW01, 9653, NCT02178241
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0103-018, NCI-2014-02470, NCT02236195
Surgery with or without Postoperative Intensity Modulated Radiation Therapy in Treating Patients with Urothelial Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NRG-GU001, NCI-2014-02061, NCT02316548
Palbociclib in Treating Patients with Metastatic Urothelial Cancer after First-Line Chemotherapy Failure
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1406, NCI-2015-00532, 14-2196, WI187190, NCT02334527
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-052, NCI-2015-00614, 2014-002206-20, NCT02335424
Start Over